CervoMed Inc. — Form 10-Q
Filed August 7, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On June 8, 2026, CervoMed amended its 2025 Equity Incentive Plan, effective upon shareholder approval at the 2026 Annual Meeting. The base share pool was set at 2,800,000 shares. Individual participant grants are capped at 400,000 shares per calendar year; non-employee director compensation (equity + cash) is capped at $750,000 annually ($1,000,000 in year of initial appointment). No other material details regarding prior pool size, dilution impact, or transaction context are disclosed in the exhibits.
Why this rating
Equity plan amendments are routine governance. At $39.9M market cap, 2.8M shares is material dilution, but no prior baseline given; cannot assess net change in dilution. Standard disclosure.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.